Paige Britt

Nivolumab plus AVD shows significant improvement in progression-free survival for advanced Hodgkin lymphoma, establishing it as a preferred treatment option.

Spatial transcriptome sequencing uncovers distinct tumor microenvironment subtypes in angioimmunoblastic T-cell lymphoma, enhancing patient stratification and immunotherapy strategies.

The SCORES trial reveals suvemcitug significantly enhances survival and disease control in patients with platinum-resistant recurrent ovarian cancer.

A systematic review reveals PARP inhibitors improve progression-free survival in advanced ovarian cancer but lack overall survival benefits, highlighting treatment variability.

ZUMA-14 trial reveals promising efficacy and safety of axi-cel and rituximab combination therapy for refractory large B-cell lymphoma patients.

Experts explore evolving treatment strategies for head and neck squamous cell carcinoma, emphasizing biomarker analysis and the importance of evidence-based guidelines.

Novel small molecule inhibitors show promising efficacy in endometrial cancer, with ongoing trials expanding treatment options for challenging patient populations.

FDA meeting guides Plus Therapeutics in advancing rhenium Re 186 obisbemeda for leptomeningeal metastases, paving the way for pivotal trials.

A groundbreaking blood test for colorectal cancer shows enhanced sensitivity, promising earlier detection and improved patient outcomes in upcoming studies.

Atossa Therapeutics advances Z-endoxifen for metastatic breast cancer, showing promise in clinical trials and receiving FDA approval to proceed with studies.

A recent analysis highlights the efficacy of melphalan/HDS for metastatic uveal melanoma, showing improved outcomes in patients with lower hepatic tumor burden.

A phase 2 study reveals that combining brentuximab vedotin with gemcitabine shows promising efficacy and safety for relapsed peripheral T-cell lymphoma patients.

New research reveals that combining midostaurin with standard chemotherapy significantly improves survival rates and reduces minimal residual disease in AML patients.

A phase 2 trial shows ribociclib and letrozole effectively treat recurrent low-grade serous carcinoma, achieving significant response rates and durable control.

A groundbreaking study reveals that ultrasensitive ctDNA assays significantly enhance prognosis for large B-cell lymphoma, outperforming traditional PET assessments.

Research uncovers distinct sex-based differences in exosomal ncRNA dysregulation in multiple myeloma, highlighting the need for personalized treatment strategies.

Hematologic oncology sees breakthroughs in treatment efficacy and regulatory challenges, highlighting advancements in BTK degraders and essential thrombocythemia therapies.

Discover groundbreaking advancements in urologic oncology, including new standards for prostate, kidney, and bladder cancer treatments that enhance patient outcomes.

FDA approves mosunetuzumab-axgb for quick subcutaneous treatment of relapsed follicular lymphoma, enhancing patient care and reducing clinic time.

Pirtobrutinib shows significant efficacy and safety in treating relapsed/refractory follicular lymphoma, with promising response rates and durable outcomes.

FDA approves CBI-1214 for colorectal cancer, enabling fast-tracked clinical trials and highlighting innovative T-cell engager technology.

Ultrasensitive ctDNA analysis reveals early predictive insights for immunotherapy outcomes in advanced solid tumors, enhancing patient management and survival predictions.

Interim results reveal RAD 101's promising potential in accurately diagnosing brain metastases, enhancing treatment decisions for patients.

PLT012, a groundbreaking anti-CD36 antibody, enters clinical trials to enhance immune responses in solid tumors, promising new hope for cancer treatment.

Roxadustat receives orphan drug designation for myelodysplastic syndromes, highlighting its potential to improve transfusion independence in patients.

A groundbreaking blood test for early breast cancer detection shows exceptional accuracy, outperforming traditional mammography, especially in dense breast tissue.

FDA approves T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, showing significant improvements in progression-free survival and response rates.

A phase 3 study is evaluating olverembatinib with chemotherapy for treating Philadelphia chromosome–positive acute lymphoblastic leukemia, showing promising efficacy and safety.

New research reveals hormone replacement therapy may lower breast cancer risk in BRCA carriers, challenging existing medical guidelines on HRT use.

FDA and EMA approve AVC-203, a groundbreaking CAR-T therapy targeting B-cell malignancies, promising enhanced safety and scalability for patients.